Loading...
Formycon Community
XTRA:FYB Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
Community Investing Ideas
New Approvals And Regional Expansion Will Create Future Opportunities
Key Takeaways Waiving the Phase III study for FYB206 cuts significant R&D costs, improving net margins and freeing capital for other uses. Strategic regional expansions and targeted product introductions, like the FYB201 syringe, boost market penetration and revenue potential.Read more
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
€35.69
39.9% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
22.08% p.a.
Profit Margin
28.59%
Future PE
26.63x
Share price in 2028
€54.66